STOCK TITAN

Inozyme Pharma, Inc. - $INZY STOCK NEWS

Welcome to our dedicated page for Inozyme Pharma news (Ticker: $INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inozyme Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inozyme Pharma's position in the market.

Rhea-AI Summary
Inozyme Pharma, Inc. reports financial results for Q3 2023, highlighting the progress of INZ-701 in pediatric and adult patients with ENPP1 Deficiency and ABCC6 Deficiency, with topline data expected in 2024 and 2025. Cash position remains strong at $192.4 million, funding operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
-
Rhea-AI Summary
Inozyme Pharma, Inc. has granted stock options to new employees as part of its 2023 Inducement Stock Incentive Plan. The company's compensation committee granted nonstatutory stock options to three new employees, allowing them to purchase up to a total of 116,500 shares of the company's common stock. The exercise price is set at $2.89 per share, with a ten-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Inozyme Pharma announces oral presentation at the American Society of Nephrology Kidney Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
Rhea-AI Summary
Inozyme Pharma highlights inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomic England's Generation Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
-
Rhea-AI Summary
Inozyme Pharma to present three posters at ASBMR 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
-
Rhea-AI Summary
Inozyme Pharma announces positive interim data from ongoing clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency (PXE). The trials demonstrate safety, increased PPi levels, and trends of clinical improvement. The data is highly encouraging and supports the potential for INZ-701 to treat rickets and address symptoms in both adult and pediatric patients. The drug exhibits a favorable safety profile and immunogenicity profile. The company will host a conference call and webcast to discuss the updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
Rhea-AI Summary
Inozyme Pharma to share interim data updates from ongoing trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency. Investor and Analyst Event on September 26, 2023. Webcast and conference call to review Phase 2 data. Safety and pharmacodynamic data update for Phase 1/2 trial of INZ-701 in ABCC6 Deficiency patients. Accessible through Inozyme's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.64%
Tags
conferences
-
Rhea-AI Summary
Inozyme Pharma grants stock options to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Summary
Inozyme Pharma to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
conferences
Rhea-AI Summary
Inozyme Pharma, Inc. (Nasdaq: INZY) reported financial results for the second quarter ended June 30, 2023, and provided business highlights. They expect interim data readouts from Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency in September 2023, and initiation of the ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency in October 2023. The company expects their cash position to fund cash flow requirements into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
Inozyme Pharma, Inc.

Nasdaq:INZY

INZY Rankings

INZY Stock Data

301.85M
34.13M
0.66%
92.95%
4.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON

About INZY

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.